Titre : Régions 5' non traduites

Régions 5' non traduites : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Régions 5' non traduites : Questions médicales les plus fréquentes", "headline": "Régions 5' non traduites : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Régions 5' non traduites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-19", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Régions 5' non traduites" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Régions non traduites", "url": "https://questionsmedicales.fr/mesh/D020506", "about": { "@type": "MedicalCondition", "name": "Régions non traduites", "code": { "@type": "MedicalCode", "code": "D020506", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340.137.910" } } }, "about": { "@type": "MedicalCondition", "name": "Régions 5' non traduites", "alternateName": "5' Untranslated Regions", "code": { "@type": "MedicalCode", "code": "D020121", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nicola Whiffin", "url": "https://questionsmedicales.fr/author/Nicola%20Whiffin", "affiliation": { "@type": "Organization", "name": "National Heart and Lung Institute and MRC London Institute of Medical Science, Imperial College London, London W12 0NN, UK." } }, { "@type": "Person", "name": "Olga A Nikolaitchik", "url": "https://questionsmedicales.fr/author/Olga%20A%20Nikolaitchik", "affiliation": { "@type": "Organization", "name": "Viral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA." } }, { "@type": "Person", "name": "Vinay K Pathak", "url": "https://questionsmedicales.fr/author/Vinay%20K%20Pathak", "affiliation": { "@type": "Organization", "name": "Viral Mutation Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA." } }, { "@type": "Person", "name": "Wei-Shau Hu", "url": "https://questionsmedicales.fr/author/Wei-Shau%20Hu", "affiliation": { "@type": "Organization", "name": "Viral Recombination Section, HIV Dynamics and Replication Program, National Cancer Institute, Frederick, Maryland, USA." } }, { "@type": "Person", "name": "William E Tapprich", "url": "https://questionsmedicales.fr/author/William%20E%20Tapprich", "affiliation": { "@type": "Organization", "name": "Biology Department, University of Nebraska at Omaha, Omaha, Nebraska, USA wtapprich@unomaha.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use.", "datePublished": "2022-10-13", "url": "https://questionsmedicales.fr/article/36229762", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11606-022-07793-x" } }, { "@type": "ScholarlyArticle", "name": "Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36067724", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugpo.2022.103847" } }, { "@type": "ScholarlyArticle", "name": "Preventing controlled substance diversion in perioperative settings: a narrative review.", "datePublished": "2023-09-15", "url": "https://questionsmedicales.fr/article/37715047", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12630-023-02574-4" } }, { "@type": "ScholarlyArticle", "name": "A Source Control Model for Treatment-Resistant Substance Use Disorder.", "datePublished": "2024-07-16", "url": "https://questionsmedicales.fr/article/39012014", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/ADM.0000000000001344" } }, { "@type": "ScholarlyArticle", "name": "Liquid Marble as an Amphibious Carrier for the Controlled Delivery and Release of Substances.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36240141", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.langmuir.2c02305" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Génome", "item": "https://questionsmedicales.fr/mesh/D016678" }, { "@type": "ListItem", "position": 5, "name": "Composants de génome", "item": "https://questionsmedicales.fr/mesh/D040481" }, { "@type": "ListItem", "position": 6, "name": "Gènes", "item": "https://questionsmedicales.fr/mesh/D005796" }, { "@type": "ListItem", "position": 7, "name": "Composants de gène", "item": "https://questionsmedicales.fr/mesh/D040461" }, { "@type": "ListItem", "position": 8, "name": "Régions non traduites", "item": "https://questionsmedicales.fr/mesh/D020506" }, { "@type": "ListItem", "position": 9, "name": "Régions 5' non traduites", "item": "https://questionsmedicales.fr/mesh/D020121" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Régions 5' non traduites - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Régions 5' non traduites", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Régions 5' non traduites", "description": "Comment identifier les 5' UTR dans un gène ?\nQuels tests sont utilisés pour étudier les 5' UTR ?\nLes 5' UTR sont-elles visibles sur des électrophorèses ?\nPeut-on détecter des mutations dans les 5' UTR ?\nQuel rôle jouent les 5' UTR dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Régions 5' non traduites", "description": "Les 5' UTR sont-elles liées à des symptômes cliniques ?\nQuels symptômes peuvent indiquer un problème avec les 5' UTR ?\nLes 5' UTR affectent-elles la réponse aux traitements ?\nPeut-on relier les 5' UTR à des syndromes spécifiques ?\nLes 5' UTR sont-elles impliquées dans des cancers ?", "url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Régions 5' non traduites", "description": "Peut-on prévenir les anomalies des 5' UTR ?\nY a-t-il des facteurs environnementaux affectant les 5' UTR ?\nComment le mode de vie influence-t-il les 5' UTR ?\nLes dépistages génétiques aident-ils à prévenir les problèmes liés aux 5' UTR ?\nLes vaccinations influencent-elles les 5' UTR ?", "url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Régions 5' non traduites", "description": "Comment les traitements ciblent-ils les 5' UTR ?\nLes médicaments peuvent-ils interagir avec les 5' UTR ?\nY a-t-il des traitements pour corriger les anomalies des 5' UTR ?\nLes traitements ciblant les 5' UTR sont-ils efficaces ?\nLes 5' UTR influencent-elles la résistance aux traitements ?", "url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Régions 5' non traduites", "description": "Quelles complications peuvent survenir avec des anomalies des 5' UTR ?\nLes anomalies des 5' UTR peuvent-elles entraîner des complications héréditaires ?\nComment les 5' UTR affectent-elles le pronostic des maladies ?\nLes complications liées aux 5' UTR sont-elles réversibles ?\nLes 5' UTR sont-elles impliquées dans des complications post-thérapeutiques ?", "url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Régions 5' non traduites", "description": "Quels sont les facteurs de risque pour les anomalies des 5' UTR ?\nL'âge est-il un facteur de risque pour les anomalies des 5' UTR ?\nLes habitudes alimentaires influencent-elles les 5' UTR ?\nLe stress peut-il affecter les 5' UTR ?\nLes infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?", "url": "https://questionsmedicales.fr/mesh/D020121?mesh_terms=Controlled+Substances&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les 5' UTR dans un gène ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les 5' UTR peuvent être identifiées par séquençage d'ARN et analyse bioinformatique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour étudier les 5' UTR ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent le RT-PCR et les analyses de l'expression génique." } }, { "@type": "Question", "name": "Les 5' UTR sont-elles visibles sur des électrophorèses ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être visualisées sur des gels d'électrophorèse après amplification." } }, { "@type": "Question", "name": "Peut-on détecter des mutations dans les 5' UTR ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations peuvent être détectées par séquençage ciblé des régions 5' UTR." } }, { "@type": "Question", "name": "Quel rôle jouent les 5' UTR dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles influencent la régulation de l'expression génique, affectant le diagnostic de maladies." } }, { "@type": "Question", "name": "Les 5' UTR sont-elles liées à des symptômes cliniques ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans les 5' UTR peuvent entraîner des symptômes variés selon le gène affecté." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec les 5' UTR ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes peuvent inclure des troubles métaboliques ou des maladies neurodégénératives." } }, { "@type": "Question", "name": "Les 5' UTR affectent-elles la réponse aux traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des variations dans les 5' UTR peuvent influencer l'efficacité des traitements médicamenteux." } }, { "@type": "Question", "name": "Peut-on relier les 5' UTR à des syndromes spécifiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations dans les 5' UTR sont associées à des syndromes génétiques spécifiques." } }, { "@type": "Question", "name": "Les 5' UTR sont-elles impliquées dans des cancers ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des altérations dans les 5' UTR peuvent contribuer à la carcinogenèse dans certains cancers." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des 5' UTR ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par des conseils génétiques et un suivi médical pour les familles à risque." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux affectant les 5' UTR ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des gènes liés aux 5' UTR." } }, { "@type": "Question", "name": "Comment le mode de vie influence-t-il les 5' UTR ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque d'anomalies génétiques, y compris celles des 5' UTR." } }, { "@type": "Question", "name": "Les dépistages génétiques aident-ils à prévenir les problèmes liés aux 5' UTR ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage génétique peut identifier les risques et permettre une intervention précoce." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles les 5' UTR ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations n'affectent pas directement les 5' UTR, mais protègent contre certaines maladies." } }, { "@type": "Question", "name": "Comment les traitements ciblent-ils les 5' UTR ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des oligonucléotides peuvent cibler les 5' UTR pour moduler l'expression." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils interagir avec les 5' UTR ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent moduler l'activité des 5' UTR, influençant la traduction." } }, { "@type": "Question", "name": "Y a-t-il des traitements pour corriger les anomalies des 5' UTR ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches de thérapie génique sont en développement pour corriger ces anomalies." } }, { "@type": "Question", "name": "Les traitements ciblant les 5' UTR sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité dépend du type de mutation et du contexte biologique de la maladie." } }, { "@type": "Question", "name": "Les 5' UTR influencent-elles la résistance aux traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des variations dans les 5' UTR peuvent être liées à la résistance aux traitements anticancéreux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies des 5' UTR ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des maladies métaboliques, des cancers ou des troubles neurologiques." } }, { "@type": "Question", "name": "Les anomalies des 5' UTR peuvent-elles entraîner des complications héréditaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies peuvent être transmises et causer des complications héréditaires." } }, { "@type": "Question", "name": "Comment les 5' UTR affectent-elles le pronostic des maladies ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les variations dans les 5' UTR peuvent influencer le pronostic et la réponse au traitement." } }, { "@type": "Question", "name": "Les complications liées aux 5' UTR sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la maladie." } }, { "@type": "Question", "name": "Les 5' UTR sont-elles impliquées dans des complications post-thérapeutiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des modifications dans les 5' UTR peuvent contribuer à des complications après traitement." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des 5' UTR ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et des mutations." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour les anomalies des 5' UTR ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé peut augmenter le risque de mutations dans les 5' UTR et d'autres gènes." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles les 5' UTR ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent affecter l'expression des gènes, y compris les 5' UTR." } }, { "@type": "Question", "name": "Le stress peut-il affecter les 5' UTR ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut influencer l'expression génique et potentiellement affecter les 5' UTR." } }, { "@type": "Question", "name": "Les infections virales sont-elles un facteur de risque pour les anomalies des 5' UTR ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent induire des modifications dans les 5' UTR, augmentant les risques." } } ] } ] }

Sources (10000 au total)

National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use.

Despite widespread adoption of state prescription drug monitoring programs (PDMPs), it is unclear how often PDMPs are accessed through an electronic health record system (EHR-PDMP integration), or whe... To produce national-level estimates on the use of PDMPs among office-based physicians and benefits associated with their use.... We use nationally representative survey data to produce descriptive statistics on PDMP use and associated benefits among office-based physicians in the USA.... 1398 office-based physicians who prescribe controlled substances.... We examined physician-reported ease and frequency of PDMP use, and how EHR-PDMP integration affects frequency and ease of use. Multivariate models were used to assess whether characteristics of PDMP u... In 2019, two-thirds of office-based physicians in the USA reported frequent use of their state PDMP and over three-quarters reported they were easy to use. Both frequency and ease of use were positive... Our findings suggest efforts to make PDMPs easier to access and use aided physicians in making informed clinical decisions that may not be captured by reduced prescribing alone. Efforts to further inc...

Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline.

Prescription Drug Monitoring Programs (PDMP) are electronic databases that are used to track and monitor the prescribing and dispensing of controlled substances, such as opioid analgesics and benzodia... This study aimed to better understand how people who use prescription medications extramedically and their loved ones give meaning to their consumption and their treatment experiences and concerns in ... Nineteen audio recordings of telephone calls made to the PDMP Pharmaceutical Helpline were transcribed and thematically analysed.... Patients and their families were hopeful that PDMP would stop the extra medical use of medications. However, many were deeply concerned about how they would cope with withdrawal or life stressors with... PDMP have the potential to both assist and harm patients whose prescription medication use has been identified as 'risky' by the PDMP. The findings from this study suggest that clear and open communic...

Preventing controlled substance diversion in perioperative settings: a narrative review.

Diversion of controlled substances in the perioperative setting is an ongoing challenge, with consequences for patients, anesthesiologists, perioperative staff, and health care facilities alike. Perio... We performed a targeted literature search in PubMed MEDLINE, Embase, Scopus, Web of Science, the Cochrane Register of Controlled trials, and the Cochrane Database of Systematic Reviews, as well as a m... Many strategies have been described for preventing diversion in perioperative settings, and these are broadly categorized into: education, distribution, auditing, or provider screening. Some of these ... Although awareness of perioperative controlled substance diversion has been improving, there are too few data to suggest an optimal approach. Anesthesia departments will need to work collaboratively w...

Substance use and driver fatality in Norway: An expanded case-control study.

Using alcohol or psychoactive drugs before driving a motor vehicle may increase the risk of crash involvement, injury, and death. This is better documented for alcohol than for drugs. The aim of this ... We collected data on alcohol and drug use from all 1197 drivers of cars and vans who were fatally injured in road traffic crashes in Norway between 2005 and 2020 ('cases') by analyzing blood samples o... Compared to no substance use, the aOR (95% CI) for driver fatality was for alcohol 91 (61-137), stimulants (primarily amphetamines) aOR 22 (9-56), benzodiazepines and z-hypnotics (BZDs) aOR 4.0 (2.7-5... Alcohol and polysubstance use are the most important predictors of fatal injury, followed by stimulants....